Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.

Fastner G, Sedlmayer F, Widder J, Metz M, Geinitz H, Kapp K, Fesl C, Sölkner L, Greil R, Jakesz R, Kwasny W, Heck D, Bjelic-Radisic V, Balic M, Stöger H, Wieder U, Zwrtek R, Semmler D, Horvath W, Melbinger-Zeinitzer E, Wiesholzer M, Wette V, Gnant M.

Eur J Cancer. 2020 Jan 18;127:12-20. doi: 10.1016/j.ejca.2019.11.024. [Epub ahead of print]

PMID:
31962198
2.

Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype.

Čipak Gašparović A, Milković L, Dandachi N, Stanzer S, Pezdirc I, Vrančić J, Šitić S, Suppan C, Balic M.

Antioxidants (Basel). 2019 Dec 11;8(12). pii: E633. doi: 10.3390/antiox8120633.

3.

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.

Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N.

Breast Care (Basel). 2019 Apr;14(2):103-110. doi: 10.1159/000499931. Epub 2019 Apr 4. Review.

4.

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.

Müller HD, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R, Hauser H, Dandachi N, Prein K, Stoeger H, Lax S, Balic M.

Ann Surg Oncol. 2019 Dec;26(13):4274-4283. doi: 10.1245/s10434-019-07741-w. Epub 2019 Aug 26.

5.

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.

Suppan C, Brcic I, Tiran V, Mueller HD, Posch F, Auer M, Ercan E, Ulz P, Cote RJ, Datar RH, Dandachi N, Heitzer E, Balic M.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1171. doi: 10.3390/cancers11081171.

6.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
7.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M.

Clin Cancer Res. 2019 Jul 1;25(13):3865-3872. doi: 10.1158/1078-0432.CCR-19-0376. Epub 2019 May 7.

PMID:
31064782
8.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
9.

Volume Computed Tomography Perfusion Imaging: Evaluation of the Significance in Oncologic Follow-up of Metastasizing Renal Cell Carcinoma in the Early Period of Targeted Therapy - Preliminary Results.

Vehabovic-Delic A, Balic M, Rossmann C, Bauernhofer T, Deutschmann HA, Schoellnast H.

J Comput Assist Tomogr. 2019 May/Jun;43(3):493-498. doi: 10.1097/RCT.0000000000000848.

PMID:
30762651
10.

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R.

BMC Cancer. 2018 Nov 6;18(1):1074. doi: 10.1186/s12885-018-4979-0.

11.

News from ASCO 2018.

Balic M, Dedic N, De Mattos-Arruda L, Gampenrieder S.

Breast Care (Basel). 2018 Aug;13(4):298-302. doi: 10.1159/000491564. Epub 2018 Jul 12. No abstract available.

12.

Circulating Tumor Cells: Strategies for Capture, Analyses, and Propagation.

Agarwal A, Balic M, El-Ashry D, Cote RJ.

Cancer J. 2018 Mar/Apr;24(2):70-77. doi: 10.1097/PPO.0000000000000310. Review.

13.

Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.

Brcic L, Stanzer S, Krenbek D, Gruber-Moesenbacher U, Absenger G, Quehenberger F, Valipour A, Lindenmann J, Stoeger H, Al Effah M, Fediuk M, Balic M, Popper HH.

Virchows Arch. 2018 Apr;472(4):589-598. doi: 10.1007/s00428-018-2326-0. Epub 2018 Mar 8.

14.

Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.

Benezeder T, Tiran V, Treitler AAN, Suppan C, Rossmann C, Stoeger H, Cote RJ, Datar RH, Balic M, Dandachi N.

Oncotarget. 2017 Sep 30;8(54):92483-92496. doi: 10.18632/oncotarget.21426. eCollection 2017 Nov 3.

15.

Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.

Dandachi N, Tiran V, Lindenmann J, Brcic L, Fink-Neuboeck N, Kashofer K, Absenger G, Bezan A, Cote RJ, Datar R, Balic M.

Lung Cancer. 2017 Nov;113:152-157. doi: 10.1016/j.lungcan.2017.10.003. Epub 2017 Oct 9.

PMID:
29110843
16.

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.

Tiran V, Lindenmann J, Brcic L, Heitzer E, Stanzer S, Tabrizi-Wizsy NG, Stacher E, Stoeger H, Popper HH, Balic M, Dandachi N.

Sci Rep. 2017 Aug 30;7(1):10040. doi: 10.1038/s41598-017-09929-0.

17.

Biosimilars in the Treatment of Breast Cancer.

Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E.

Breast Care (Basel). 2017 Jul;12(3):192-194. doi: 10.1159/000477926. Epub 2017 Jun 13. No abstract available.

18.

Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.

Suppan C, Balic M.

Memo. 2017;10(2):82-85. doi: 10.1007/s12254-017-0328-2. Epub 2017 Apr 25. Review.

19.

Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.

Tiran V, Stanzer S, Heitzer E, Meilinger M, Rossmann C, Lax S, Tsybrovskyy O, Dandachi N, Balic M.

PLoS One. 2017 Apr 19;12(4):e0175223. doi: 10.1371/journal.pone.0175223. eCollection 2017.

20.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

Supplemental Content

Loading ...
Support Center